Organoid-based precision medicine for advanced, pretreated solid cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Organotreat is a multicenter prospective program that uses tumor-derived organoids to test a panel of drugs and inform therapy choices after a biopsy. Organoids are grown and exposed to chemotherapy, hormonal, and targeted therapies to create a chemogram, which is reviewed by a Chemogram Tumor Board to guide treatment. Patients start a standard therapy line, and if disease progresses or toxicity is unacceptable, the CTB-guided regimen may be used. The program spans three studies: ORGANOTREAT-01 (advanced colorectal cancer), ORGANOTREAT-02A (CRC or PDAC), and ORGANOTREAT-02B (other solid cancers with adequate organoid take rate). Patients are followed until progression, intolerable toxicity, death, or study termination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* ECOG performance status 0-1
* Life expectancy \>3 months
* Histologically-confirmed, unresectable, locally advanced or metastatic solid tumor

  * ORGANOTREAT-01: CRC
  * ORGANOTREAT-02A: Colorectal adenocarcinoma (CRC) or pancreatic ductal adenocarcinoma (PDAC)
  * ORGANOTREAT-02B: solid cancers with a PDO take-on rate ≥50%:

    * Stratum 1: PDAC
    * Stratum 2: CRC
    * Other strata: to be added by protocol amendment
* ≥1 measurable lesion according to RECIST v1.1
* ≥1 tumor site accessible to biopsy without significant risk, outside from lung lesion
* Patients are to be biopsied before the start or within the 3 first weeks of the SoC line.
* Failure (disease progression or intolerance) or contraindication to validated treatments in the advanced setting; patients MUST be still eligible for at least 1 (ORGANOTREAT-01 and -2A) or 2 (ORGANOTREAT-02B) validated systemic treatment lines according to approved guidelines:

  * CRC (ORGANOTREAT-01): failure (disease progression or intolerance) or contraindication to fluoropyrimidines, oxaliplatin, irinotecan, anti-EGFR (in RAS wild-type tumors), anti-BRAF (in BRAF V600E mutated tumors), and antiangiogenics; patients must be still eligible for trifluridine-tipiracil and/or regorafenib
  * CRC (ORGANOTREAT-2A): failure (disease progression or intolerance) or contraindication to fluoropyrimidines, oxaliplatin, irinotecan, anti-EGFR (in RAS wild-type tumors), anti-BRAF (in BRAF V600E mutated tumors), and trifluridine-tipiracil/bevacizumab; patients must be still eligible for regorafenib
  * PDAC (ORGANOTREAT-2A): Patients will be included at the beginning of their second line of standard therapy
  * PDAC (ORGANOTREAT-02B stratum 1): patients will be included at the beginning of their first- or second-line of therapy
  * Specifications for supplementary tumor strata in ORGANOTREAT-02 will be defined by protocol amendment
* Adequate hepatic, renal and hematological functions (AST/ALT \< 2.5 ULN (5 ULN in cases of liver metastases); Total bilirubin \< 1.5 ULN; Albumin \> 30 g/L; International normalized ratio (INR) \<1.5 ULN; Calculated creatinine clearance \>50 mL/min; Absolute neutrophil count \>1000/mm3, platelets \>100 000/mm3, hemoglobin \>9 g/dL) To be performed until 7 days before enrollment
* Informed consent signed by the patient or his/her legal representative
* Affiliation to or beneficiary of a social security system
* A female participant is eligible to participate if she is not pregnant not breastfeeding, and

  1. Not a woman of childbearing potential (WOCBP) OR
  2. A WOCBP should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* A WOCBP must agree to follow the contraceptive guidance or abstain from heterosexual activity during the treatment period and for at least 180 days, after the last dose of treatment.

Exclusion Criteria:

* History of other invasive cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix
* Concomitant medications/comorbidities that may prevent the patient from being biopsied
* Patients with brain or meningeal metastasis, unless definitive therapy occurred more than 6 months ago and with a confirmation of tumoral control and absence of symptoms within 4 weeks of starting study treatment
* Pregnancy or breast-feeding
* Privation of liberty or guardianship
* Geographical, social or psychological reasons precluding study participation and monitoring
* Coagulation abnormality prohibiting a biopsy

Where it's running

• Institut Bergonié
  Bordeaux, France, France Recruiting
• Centre Oscar Lambret
  Lille, France, France Recruiting
• Hôpital Saint Louis
  Paris, France, France Recruiting
• Hôpital Pitié-Salpêtrière
  Paris, France, France Recruiting
• Hôpital St Antoine
  Paris, France, France Recruiting
• Institut Godinot
  Reims, France, France Recruiting

Study contacts

• Study coordinator: Michel Ducreux, MD
• Email: Michel.Ducreux@gustaveroussy.fr
• Phone: +33 (0)1 42 11 50 42

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Cohort for people with chronic myelomonocytic leukemia

  This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Amiens and 23 other locations · NCT07512882

• ASP3082 for advanced KRAS G12D non-small-cell lung and pancreatic cancers

  This study tests whether the experimental drug ASP3082, given once-weekly by IV, helps people with advanced or metastatic non‑small‑cell lung cancer or pancreatic ductal adenocarcinoma that carry a KRAS G12D mutation.

  Recruiting at 6 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France and 6 other locations · NCT07483983

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• Valemetostat for selected solid tumors with SWI/SNF gene alterations

  This trial will test whether valemetostat, an EZH1/2 inhibitor, can slow or stop growth in adults whose progressive solid tumors have specific SWI/SNF‑related gene changes.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 3 other locations · NCT07303387

• Short-term preoperative elacestrant alone versus elacestrant plus ovarian suppression for premenopausal early-stage ER+/HER2- breast cancer

  We will test whether 4 weeks of elacestrant alone or with ovarian suppression lowers the tumor proliferation marker Ki67 in premenopausal women with stage I–II ER+/HER2- breast cancer.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT07159451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.